KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash & Equivalents (2016 - 2026)

TherapeuticsMD filings provide 17 years of Cash & Equivalents readings, the most recent being $8.4 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 46.54% to $8.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.4 million, a 46.54% increase, with the full-year FY2025 number at $7.5 million, up 47.91% from a year prior.
  • Cash & Equivalents hit $8.4 million in Q1 2026 for TherapeuticsMD, up from $7.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $49.3 million in Q4 2022 to a low of $4.3 million in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $7.5 million (2025), compared with a mean of $14.4 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 91.23% in 2023 and later skyrocketed 47.91% in 2025.
  • TherapeuticsMD's Cash & Equivalents stood at $49.3 million in 2022, then crashed by 91.23% to $4.3 million in 2023, then rose by 16.92% to $5.1 million in 2024, then skyrocketed by 47.91% to $7.5 million in 2025, then increased by 12.51% to $8.4 million in 2026.
  • The last three reported values for Cash & Equivalents were $8.4 million (Q1 2026), $7.5 million (Q4 2025), and $7.1 million (Q3 2025) per Business Quant data.